Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Acamprosate(click to collapse)
1/4 selected
Acamprosate
Campral
NMDA/GABA Modulator
FDA-approved indications
- Maintenance of alcohol abstinence (alcohol dependence; abstinent at start; adults)
Off-label uses
- Tinnitus (investigational)
- Anxiety in alcohol recovery
Half-life20 to 33 hours
Decision GuideWhen to pick each / when to consider an alternative
Acamprosate
Consider when
- Alcohol use disorder maintenance — FDA-approved for maintaining abstinence in AUD patients who are already abstinent at treatment start
- Hepatic impairment when naltrexone is contraindicated — renally excreted with no hepatic metabolism; safe in liver disease
- Polypharmacy concerns — no CYP metabolism, no protein binding, no drug interactions; uniquely clean pharmacokinetic profile
- Glutamatergic dysregulation targeted — NMDA modulation normalizes hyperglutamatergic state of early abstinence; unique mechanism
- +1 more
Consider an alternative when
- Severe renal impairment (CrCl <30) — contraindicated; 100% renally excreted unchanged; no dose adjustment possible
- TID dosing is an adherence barrier — 666 mg TID (6 tablets/day) is burdensome; naltrexone offers QD or monthly IM
- Active drinking — not effective for reducing drinking in active use; designed for abstinence maintenance only
- Suicidal ideation risk — post-marketing reports of suicidality; monitor mood in early treatment
- +1 more
| Axis | Acamprosate NMDA-modulator |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
| CNS | |
Activation / insomnia | |
| Endocrine | |
Renal effects | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |